abdominal distention (RR = 0.39, 95% CI: 0.26-0.59)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobaconstipation (RR = 0.32, 95% CI: 0.18-0.55)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobaSpecifically, it reduced the incidence of some gastrointestinal adverse effects and nonspecific adverse effects, including diarrhea (RR = 0.28, 95% CI: 0.22-0.36)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobanausea (RR = 0.59, 95% CI: 0.36-0.97)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobarash (RR = 0.49, 95% CI: 0.28-0.86)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobaS. boulardii supplementation to bismuth quadruple therapy significantly improved H. pylori eradication rates (RR = 1.08, 95% CI: 1.04-1.12) and reduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62).
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobareduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62)